Chemoimmunotherapy for Relapsed/Refractory and Progressive 17p13 Deleted Chronic Lymphocytic Leukemia (CLL) Combining Pentostatin, Alemtuzumab, and Low Dose Rituximab is Effective and Tolerable and Limits Loss of CD20 Expression by Circulating CLL Cells

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients with purine analogue refractory disease or TP53 dysfunction still have limited treatment options and poor survival. Alemtuzumab containing chemoimmunotherapy regimens can be effective but frequently cause serious infections. We r...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Am J Hematol
Huvudupphovsmän: Zent, Clive S., Taylor, Ronald P., Lindorfer, Margaret A., Beum, Paul V., LaPlant, Betsy, Wu, Wenting, Call, Timothy G., Bowen, Deborah A., Conte, Michael J., Frederick, Lori A., Link, Brian K., Blackwell, Sue E., Veeramani, Suresh, Baig, Nisar A., Viswanatha, David S., Weiner, George J., Witzig, Thomas E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280857/
https://ncbi.nlm.nih.gov/pubmed/24723493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23737
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk